To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Squamous cell carcinoma i… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Squamous cell carcinoma in a patient with oral lichen planus treated with topical application of tacrolimus.

Journal article
Authors Ulf Mattsson
Bengt Magnusson
Mats Jontell
Published in Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
Volume 110
Issue 1
Pages e19-25
ISSN 1528-395X
Publication year 2010
Published at Institute of Odontology
Pages e19-25
Language en
Links dx.doi.org/10.1016/j.tripleo.2010.0...
Keywords Administration, Buccal, Carcinoma, Squamous Cell, etiology, Clobetasol, administration & dosage, therapeutic use, Follow-Up Studies, Glucocorticoids, administration & dosage, therapeutic use, Humans, Immunosuppressive Agents, administration & dosage, therapeutic use, Lichen Planus, Oral, drug therapy, Male, Middle Aged, Mouth Neoplasms, etiology, Tacrolimus, administration & dosage, therapeutic use, Triamcinolone Acetonide, administration & dosage, therapeutic use
Subject categories Microbiology in the medical area, Oral pathology and forensic odontology

Abstract

Oral lichen planus (OLP) is a chronic mucosal disorder of unclear etiology. The mainstay of therapy is topical use of steroids but other immuno-modulating therapies have also been tried. One such example is topical application of tacrolimus. Tacrolimus was in 2000 approved for treatment of atopic dermatitis, but in 2005 a boxed warning was included because of a potential risk of cancer development and for lack of long-term studies of the safety of the drug. The present study describes a patient who in 2003 was diagnosed with OLP and where treatment has included an intermittent use of tacrolimus. Five years after diagnosis, the patient developed a squamous cell carcinoma in the region where tacrolimus had been applied. The possible relationship between the use of tacrolimus and cancer development and rationale to include tacrolimus in OLP treatment is discussed.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?